Fibromyalgia consensus report: Additional comments

Journal of Clinical Rheumatology

Volumn 3, Issue 6, 1997, Pages 324-327

  Yunus, Muhammad B ^a,e   Bennett, Robert M ^b   Romano, Thomas J ^c   Russell, I Jon ^d  

^a UNIVERSITY OF ILLINOIS   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c Professional Center III   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e UICOMP   (United States)

Author keywords

Causality; Consensus report; Controversy; Fibromyalgia; Management

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AMITRIPTYLINE; FLUOXETINE; NONSTEROID ANTIINFLAMMATORY AGENT; SEROTONIN AGONIST;

ARTICLE; BEHAVIOR THERAPY; COGNITIVE THERAPY; DISEASE COURSE; FIBROMYALGIA; HUMAN; KINESIOTHERAPY; LABORATORY DIAGNOSIS; MEDICAL RESEARCH; PHYSIOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 0031406333     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/00124743-199712000-00004     Document Type: Article

References (40)

1. Wolfe F. Vancouver Fibromyalgia Consensus Group. The fibromyalgia syndrome: a consensus report on fibromyalgia and disability. J Rheumatol 1996;23:534-9.
2. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: Report of the multicenter criteria committee. Arthritis Rheum 1990;33:160-72.
3. Kramer MS, Lane DA. Causal propositions in clinical research and practice. J Clin Epidemiol 1992;45:639-49.
4. Hulley SB, Cummings SR. Designing Clinical Research: an Epidemiologic Approach. Baltimore: Williams & Wilkins, 1988. p. 108-9.
5. Sadcett DL, Rosenberg WMM, Gray JAM, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn't. BMJ 1996;312:71-2.
6. Bennett RM. Disabling fibromyalgia: appearance versus reality (editorial). J Rheumatol 1993;11:1821.
7. Romano TJ. Clinical experiences with post-traumatic fibromyalgia syndrome. W V Med J 1990;86:198-202.
8. Moldofsky H, Wong MTH, Lue FA. Litigation, sleep, symptoms and disabilities in postaccident pain (fibromyalgia). J Rheumatol 1993;20:1935-40.
9. Pellegrino MJ. Post-traumatic Fibromyalgia: A Medical Perspective. Columbus, Ohio: Anadem Publishing, 1996.
10. Wolfe F. Post-traumatic fibromyalgia: a case report narrated by the patient. Arthritis Care Res 1994;7:161-5.
11. Bengtsson A, Henriksson KG, Jorfeldt L, Kagedal B, Lennmarken C, Lindstrom F. Primary fibromyalgia. A clinical and laboratory study of 55 patients. Scand J Rheumatol 1986;15:340-7.
12. Greenfield S, Fitzcharles M-A, Esdaile JM. Reactive fibromyalgia syndrome. Arthritis Rheum 1992;35:678-81.
13. Yunus MB, Aldag JC. Clinical and psychological features of regional fibromyalgia: comparison with fibromyalgia syndrome (abstr). Arthritis Rheum 1993;36:S221.
14. Buskila D, Neumann L, Vaisberg G, Alkalay D, Wolfe F. Increased rates of fibromyalgia following cervical spine injury. Arthritis Rheum 1997;40:446-52.
15. Yunus MB. Towards a model of pathophysiology of fibromyalgia: aberrant central pain mechanisms with peripheral modulation. J Rheumatol 1992;19:846-50.
16. Coderre TJ, Katz J, Vaccarino AL, Melzack R. Contribution of central neuroplasticity to pathological pain: review of clinical and experimental evidence. Pain 1993;52:259-85.
17. Dubner R, Ruda MA. Activity-dependent neuronal plasticity following tissue injury and inflammation. Trends Neurosci 1992;15:96-103.
18. Wolfe F. The fibromyalgia problem. Arthritis Rheum 1997;24:1247-9.
19. Torebjork HE, Lundberg LER, Lamotte RH. Central changes in processing of mechano-receptive input in capsaicin-induced secondary hyperalgesia in humans. J Physiol (Lond) 1992;448:765-80.
20. Moldofsky H. Fibromyalgia, sleep disorder and chronic fatigue syndrome. In: Block GR, Whelan J, editors. Chronic Fatigue Syndrome. Chichester: J. Wiley, 1993. p. 262-79.
21. Vaeroy H, Helle R, Forre O, Kass E, Terenius L. Elevated CSF levels of substance P and high incidence of Raynaud's phenomenon in patients with fibromyalgia: new features for diagnosis. Pain 1988;32:21-6.
22. Russell IJ, Orr MD, Littman B, Vipraio GA, Alboukrek D, Michalek JE, et al. Elevated cerebrospinal fluid levels of substance P in the fibromyalgia syndrome. Arthritis Rheum 1994;37:1593-1601.
23. Russell IJ, Michalek JE, Vipraio GA, Fletcher EM, Javors MA, Bowden CA. Platelet 3H-imipramine uptake receptor density and serum serotonin levels in patients with fibromyalgia/fibrositis syndrome. J Rheumatol 1992;19:104-9.
24. Hyrcaj, Stratz T, Muller W. Platelet 3H-imipramine uptake receptor density and serum serotonin levels in patients with fibromyalgia/fibrositis syndrome. J Rheumatol 1993;20:1986-7.
25. Kravitz HM, Katz R, Kot E, Helmke N, Fawcett J. Biochemical clues to a fibromyalgia-depression link: imipramine binding in patients with fibromyalgia or depression and in healthy controls. J Rheumatol 1992;19:1428-32.
26. Bennett RM, Clark SR, Campbell SM, Burckhardt CS. Low levels of somatomedin C in patients with fibromyalgia syndrome - a possible link between sleep and muscle pain. Arthritis Rheum 1992;35:1113-6.
27. Mountz JM, Bradley LA, Modell JG, Alexander RW, Triana-Alexander M, Aaron LA, et al. Fibromyalgia in women: abnormalities of regional cerebral blood flow in the thalamus and the caudate nucleus are associated with low pain threshold levels. Arthritis Rheum 1995; 38:926-38.
28. Willer JC, DeBroucker T, Bussel B, Roby-Brami A, Harrewyn JM. Central analgesic effect of ketoprofen in humans: electrophysiological evidence for a supraspinal mechanism in a double-blind and cross-over study. Pain 1989;38:1-7.
29. Malmberg AB, Yaksh TL. Hyperalgesia mediated by spinal glutamate or substance P receptor blocked by spinal cyclooxygenase inhibition. Science 1992;257:1276-9.
30. Goldenberg DL, Mayskiy M, Mossey CJ, Ruthazer R, Schmid C. A randomized, double-blind crossover trial of fluoxetin and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum 1996;39:1852-9.
31. Bennett, Burckhardt CS, Clark SR, O'Reilly CA, Wiens AN, Campbell SM. Group treatment of fibromyalgia: A 6 month outpatient program. J Rheumatol 1996;23:521-8.
32. Frost PA, Jessen B, Siggaard-Anderson J. A controlled double-blind comparison of mepivacaine injection versus saline injection for myofascial pain. Lancet 1980;1:499-501.
33. Drews AM, Andreasen A, Poulsen LH. Injection therapy for treatment of chronic myofascial pain: a double-blind study comparing corticosteroid versus diclofenac injections. J Musculoskel Pain 1993;1:289-94.
34. Sorensen J, Bengtsson A, Ahlner J, et al. Fibromyalgia - are there different mechanisms in the processing of pain? A double blind crossover comparison of analgesic drugs. J Rheumatol 1997;24:1615-24.
35. Granges G, Zilco P, Littlejohn GO. Fibromyalgia syndrome - assessment of the severity of the condition 2 years after diagnosis. J Rheumatol 1994;21:523-9.
36. Bengtsson A, Backman E, Lindblom B, Skogh T. Long term follow-up of fibromyalgia patients: clinical symptoms, muscular function, laboratory tests: an eight year comparison study. J Musculoskel Pain 1994;2:67-80.
37. Ledingham J, Doherty S, Doherty M. Primary fibromyalgia syndrome - an outcome study. Br J Rheumatol 1993;32:139-42.
38. Henriksson CM. Longterm effects of fibromyalgia on everyday life - A study of 56 patients. Scand J Rheumatol 1994;23:36-41.
39. Kennedy M, Felson DT. a prospective long-term study of fibromyalgia syndrome. Arthritis Rheum 1996;39:682-5.
40. Wolfe F, Anderson J, Harkness D, Bennett RM, Caro XJ, Goldenberg DL, Russell IJ, Yunus MB. Health status and disease severity in fibromyalgia: results of a six-center longitudinal study. Arthritis Rheum 1997;40:1571-9.